An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy
Jiyoon Bu, Ashita Nair, Mari Iida, Woo‐jin Jeong, Michael J. Poellmann, Kara Mudd, Luke J. Kubiatowicz, Elizabeth W. Liu, Deric L. Wheeler, Seungpyo Hong
Abstract
selectivity, as the conjugates improved the PD-L1 blockade effect and enhanced accumulation in tumor sites. Our results demonstrate that the dendrimer-mediated multivalent interaction substantially increases the binding avidity of the ICIs and thereby improves the antagonist effect, providing a novel platform for cancer immunotherapy.
Topics & Concepts
AvidityCancer immunotherapyReceptor–ligand kineticsChemistryDendrimerImmunotherapyConjugateIn vivoCancer researchMonoclonal antibodyIn vitroPharmacologyAntibodyBiophysicsImmune systemImmunologyMedicineBiochemistryReceptorBiologyMathematical analysisBiotechnologyMathematicsCancer Immunotherapy and BiomarkersPeptidase Inhibition and AnalysisRadiopharmaceutical Chemistry and Applications